NCT05876078Completed
DORAYA-HF OUS Assessment of the Doraya Catheter for the Treatment of ADHF Patients With Insufficient Response to Diuretics
DORAYA-HF EU: Assessment of the Doraya Catheter for the Treatment of Volume Overload in Acute Heart Failure Patients With Insufficient Response to Diuretics
Source: ClinicalTrials.gov · Last updated 9 Mar 2026
Brief summary (registry, in English)
The study objective is to evaluate the feasibility of the Doraya Catheter and measure clinical performance and safety endpoints, in ADHF patients deemed to have insufficient diuretic response.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 25 (actual)
- First submitted
- 16 May 2023
- Start date
- 1 Jul 2024
- Primary completion date
- 28 Feb 2026
- Lead sponsor
- Revamp Medical Ltd.
- Diseases
- Heart failure
- NCT number
- NCT05876078
What you commit to
- Study type: Interventional
- Participants enrolled: 25
- From 1 Jul 2024 to the primary completion date, 28 Feb 2026
- 10 sites in 5 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Systolic blood pressure \< 80 mmHg at the time of screening. 2. Acute myocardial infarction or acute coronary syndrome or cardiogenic shock or pleurocentesis within past 14 days or cardiovascular intervention within past 14 days. 3. Complex congenital heart disease (e.g., Tetralogy of Fallot subjects, single ventricle physiology).
- 4\. Known active myocarditis, hypertrophic obstructive cardiomyopathy, infiltrative cardiomyopathy (e.g., amyloidosis), constrictive pericarditis or cardiac tamponade.
- 5\. Severe Aortic valvular disorder (i.e., hemodynamically relevant valvular diseases such as severe stenosis \\severe regurgitation) or Severe mitral disease with planned intervention.
- 6\. Evidence of active systemic infection documented by either one of the following: fever \>38°C/100°F, or ongoing uncontrolled infection (i.e., inflammatory parameters not decreasing despite \> 48 hours of antibiotic treatment).
Other
- 7\. Moribund subject or subject with severe or deteriorating damage in more than 3 critical body systems, based on investigator's clinical judgement.
Who the study is looking for
- Subject is hospitalized with primary diagnosis of ADHF.
- N-terminal-pro-brain natriuretic peptide (NT-proBNP) ≥1,000 pg/m orvBNP≥250 pg/mL.
- Evidence of fluid overload.
- Subject insufficiently responds to IV diuretic therapy
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (10)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Heartcenter Dresden Coordinator of this site? Confirm its status | Dresden | Germany | Unknown status |
| Klinikum Fürth Coordinator of this site? Confirm its status | Fürth | Germany | Unknown status |
| UKSH Universitäres Herzzentrum Lübeck Coordinator of this site? Confirm its status | Lübeck | Germany | Unknown status |
| Universitätsmedizin der Johannes Gutenberg-Universität Mainz Coordinator of this site? Confirm its status | Mainz | Germany | Unknown status |
| Hospital Clinic de Barcelona Coordinator of this site? Confirm its status | Barcelona | Spain | Unknown status |
| Hospital Clinico Universitario de Valencia Coordinator of this site? Confirm its status | Valencia | Spain | Unknown status |
| A.O.U Pisana Cisanello Coordinator of this site? Confirm its status | Pisa | Italy | Unknown status |
| Mikulicz-Radecki University Teaching Hospital in Wrocław Coordinator of this site? Confirm its status | Wroclaw | Poland | Unknown status |
| SÚSCCH Coordinator of this site? Confirm its status | Banská Bystrica | Slovakia | Unknown status |
| CINRE s.r.o. Coordinator of this site? Confirm its status | Bratislava | Slovakia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.